Day: March 15, 2026

Pharmacovigilance Submission Documents in the United States

Globally, Pharmacovigilance (PV) is built on one central idea: the benefit–risk evaluation should not stop at approval; it must continue through the full drug development regulatory process and the product’s commercial lifecycle. It is no

Read More

Why Regulatory Affairs is Central to Drug Development?

Ideating, researching, and developing a drug or biologic product and bringing it to market is not a simple process. From preclinical discovery through market authorization, every stage of the drug lifecycle is critical. Across the

Read More

FDA Launches TEMPO What Medical Device Innovators Need to Know

Are you a medical device manufacturer working on digital therapeutics, remote monitoring tools, or AI-enabled care solutions for chronic disease management? If your innovation is outcome-based and driven by real-world data, you should pay close

Read More